• Filter By:
• Specialty
• Source
• Condition
• Cancer
• Infectious Disease
• Drug
• Training
• Management
• Procedure
• Therapy
• Vaccine
• Nutrition
• Country

Sex and gender differences in the use of oral anticoagulants for non-valvular atrial fibrillation: A population-based cohort study in primary health care in catalonia
Conclusion: We described the dose adequacy of patients receiving DOAC, finding a high frequency of underdosing, and significantly higher in women in comparison with men. Adherence was generally high, only with higher levels in women for rivaroxaban. Persistence during the first year of treatment was also high in general, being significantly more persistent women than men in the case of dabigatran and edoxaban. Dose inadequacy, lack of adherence and of persistence can result in less effective and safe treatments. It is necessary to conduct studies analysing sex and gender differences in health and disease.
Source: Frontiers in Pharmacology - February 7, 2023 Category: Drugs & Pharmacology Source Type: research

The use and adherence of oral anticoagulants in Primary Health Care in Catalunya, Spain: A real-world data cohort study.
CONCLUSIONS: Acenocoumarol was the most frequently prescribed OAC as first therapy in NVAF patients. Non-naive to DOAC showed better persistence than naive. Rivaroxaban showed higher proportion of adherent patients during the implementation phase than apixaban and dabigatran the lowest. PMID: 32788057 [PubMed - as supplied by publisher]
Source: Atencion Primaria - August 8, 2020 Category: Primary Care Authors: Giner-Soriano M, Cortes J, Gomez-Lumbreras A, Prat-Vallverdú O, Quijada-Manuitt MA, Morros R Tags: Aten Primaria Source Type: research

Real-life behaviour of direct oral anticoagulants in a Spanish cohort with nonvalvular atrial fibrillation: Refase Registry.
CONCLUSION: Our results of safety and efficacy are very similar to those of other previously published national registries. There were no differences among the different types of DOAC regarding outcomes. However, it was found that people taking the adjusted dose of the drug seemed to have a higher risk of death. A non-negligible proportion of patients received DOAC doses inconsistent with labelling (mostly underdose). PMID: 31335222 [PubMed - as supplied by publisher]
Source: Current Medical Research and Opinion - July 25, 2019 Category: Research Tags: Curr Med Res Opin Source Type: research

Facing real-life with direct oral anticoagulants in patients with nonvalvular atrial fibrillation: outcomes from the first observational and prospective study in a Spanish population.
CONCLUSION: This was the first prospective study that analyzed the use of all DOACs in AF patients in Spain, showing a good profile in terms of safety and effectiveness in accordance with pivotal studies. PMID: 30654626 [PubMed - as supplied by publisher]
Source: Journal of Comparative Effectiveness Research - January 20, 2019 Category: General Medicine Tags: J Comp Eff Res Source Type: research

Strategies for improving dabigatran adherence for stroke prevention in patients with non-valvular atrial fibrillation: education and drug intake reminders (FACILITA study).
CONCLUSIONS: A mixed intervention, consisting of patient education and a simple calendar reminder of drug intake, is an effective strategy to improve dabigatran therapeutic adherence in patients with NVAF. The percentage of adherence with dabigatran was high. PMID: 29384410 [PubMed - as supplied by publisher]
Source: Current Medical Research and Opinion - February 1, 2018 Category: Research Tags: Curr Med Res Opin Source Type: research

Comparison of the cost-utility of direct oral anticoagulants for the prevention of stroke in patients with atrial fibrillation in Spain.
CONCLUSIONS: All three direct anticoagulants are cost-effective against acenocoumarol. Dabigatran is economically dominant over rivaroxaban and apixaban in the Spanish setting, as it is more effective and cheaper. PMID: 28272725 [PubMed - in process]
Source: Revista de Neurologia - March 9, 2017 Category: Neurology Authors: Monreal-Bosch M, Soulard S, Crespo C, Brand S, Kansal A Tags: Rev Neurol Source Type: research